about
Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors.Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer PropertiesIn Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach.Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjectsIn vitro-in vivo correlations: general concepts, methodologies and regulatory applications.Commentary on the MID3 Good Practices Paper.A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.Population pharmacokinetic model of lithium and drug compliance assessment.Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives.Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets.Drug gastrointestinal absorption in rat: Strain and gender differences.Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules.Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid.Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients.Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers.Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat.Enhancing Oral Absorption of β-Lapachone: Progress Till Date.Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter.IVIVC approach based on carbamazepine bioequivalence studies combination.Modified nonsink equation for permeability estimation in cell monolayers: comparison with standard methods.Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles.Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures.Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug.Ion-pair strategy for enabling amifostine oral absorption: rat in situ and in vivo experiments.Systematic modelling and design evaluation of unperturbed tumour dynamics in xenografts.Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation.Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.In vitro-in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfatePharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular DegenerationEvaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: implications for dosing recommendations
P50
Q34994529-8BD0A534-F7BA-4367-AFA4-9565F36DDAEBQ35961028-2F34AD35-9BCB-45E7-9E68-8F01E8704522Q36088290-6B8C1325-F8A1-412D-98D8-43386620CEACQ37030723-786EFE20-9069-40C4-B165-898F325EB9B9Q38541574-6C7D4F61-FD28-411E-8165-D66BD79B6800Q38707591-F57E59DA-D27D-4D76-83E4-4925212F74D8Q38979581-9E58DB7A-C6E9-4A5B-923B-E10E1200B8BEQ39171975-148DF927-669D-430A-A50A-2685FC1DBA01Q39777927-F89A7EF9-C417-4CCB-A34D-9D8927CAD5A9Q40665911-BFB65AF7-2C9B-4302-AA66-F3BC01E23307Q40678840-38D5BC22-9DB5-4899-B10B-240F98612673Q40967654-9F14B15E-95C6-471C-9A65-4E5EDC98D17DQ41079136-7B75D876-BC7E-477E-9AFF-F3F155B53EC1Q41114594-12B6B3A5-1231-4D15-B3E2-38571D2C2FD4Q45893532-82E6F785-B76B-48FD-9AD7-F9659096DED2Q48432760-19A7FB95-7E7E-4614-BDC2-5A28B0D8DDBFQ49108416-6F17843B-FFB1-4220-84E8-D3DEA9F7FD58Q49923140-D0A3D257-B6A1-4E2B-A6AF-54E9D4DE9233Q50018496-1ECE1C9F-BDC4-4C0E-88AB-3651F030AE54Q51099767-A05F5A3F-0C87-4919-B448-1752B08FC3D7Q51109814-68D188D4-EA81-4034-91D5-4E8E50E45042Q51631401-2F2290B7-5E7E-4D3C-88A8-9DA1CE3BD397Q51803073-8FE3EE8F-061A-4489-9163-A1D48796FF9CQ51814010-B36F4572-CDFC-4E16-80FA-472786EE1E86Q52565559-80AE518E-1CC2-4055-BCC4-17057DCFC091Q52572372-0D8630AE-DDD9-4EA6-8FCF-1CB35A972B2FQ53795637-E8FE1C6D-E5E4-42FE-BF13-EB4088A18A4AQ84744607-4629E3A5-D6D9-4019-B6C9-9FD46B5C866CQ92344685-09029B96-B908-45E2-820A-CF96F6A0B611Q96590417-D5E6AC68-221A-4728-A12D-3F5186FAF9F8
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
V Mangas-Sanjuan
@en
V Mangas-Sanjuan
@nl
type
label
V Mangas-Sanjuan
@en
V Mangas-Sanjuan
@nl
prefLabel
V Mangas-Sanjuan
@en
V Mangas-Sanjuan
@nl
P31
P496
0000-0002-3388-5023